Compared with AZD6244 alone, AZD6244/AZD8186 had no additional impact on tumor regression in BRAF P53 mice, but it did drive a significant increase in overall survival and longevity of response relative to AZD6244 monotherapy (Supplementary Fig. S9E). The gene discussed is BRAF; the disease is neoplasm.